UNSPSC 51183109: Glyprothiazol

This classification denotes an anti-diabetic agent with the molecular formula C11H14N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1804FJN4MO, chemically known as 4-amino-n-(5-(1-methylethyl)-1,3,4-thiadiazol-2-yl)benzenesulfonamide but more generally known as glyprothiazol, which bears US NIH Compound Identifier 66458. European Medicines Agency schedules Glyprothiazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07957MIG.

UNSPSC 51183109 Glyprothiazol, a Commodity code, represents pharmaceuticals and OTC products that state and local governments procure through cooperative purchasing agreements and direct supply contracts with pharmaceutical manufacturers. State and local buyers under this code acquire generic multi-source pharmaceuticals and over-the-counter products for distribution across government facilities, including hospitals, clinics, correctional institutions, and other state and local health service operations. The work involves establishing framework agreements with manufacturers who meet FDA compliance, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) requirements, and who can supply products through authorized pharmaceutical wholesalers with established chargeback systems and electronic data interchange capability. Issuing bodies soliciting under this code include state departments of administration and multistate cooperative purchasing alliances that coordinate procurement on behalf of multiple participating state and local government members.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across multiple states including Oregon, with proposals due March 26, 2026. The solicitation requires manufacturers to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with comprehensive pricing submitted in designated Excel spreadsheet format converted to CSV, demonstrating pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. Award evaluation weights price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Awarded vendors will be effective July 1, 2026, under two-year contract terms with optional MMCAP extensions, and must maintain commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.